This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Kazuo Kanno, MD; Yukio Hirata, MD; Fujio Numano, MD; Toshiaki Emori, MD; Kazuki Ohta, MD; Masayoshi Shichiri, MD; Fumiaki Marumo, MD
Tokyo (Japan) Medical and Dental University

JAMA. 1990;264(22):2868.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

Endothelin-1 is a novel 21-residue vasoconstrictor peptide produced by vascular endothelial cells.¹ It may play important roles in the pathogenesis of hypertension² and has been shown recently to be a potent mitogen for vascular smooth-muscle cells.³

Although the causes of atherosclerosis, Buerger's disease, and Takayasu's arteritis remain elusive, the vascular lesions represented by injured vascular endothelial cells associated with abnormal proliferation of the underlying vascular smooth muscle are pathological features in common among these entities. To elucidate its pathophysiological role in the development of systemic vascular diseases, we have measured basal plasma levels of immunoreactive endothelin-1 in patients with atherosclerosis, Buerger's disease, and Takayasu's arteritis.

Study.—

Thirty-five normal subjects (16 men and 19 women, aged 53.9 [ ± 16.3] years), 13 patients with ischemic heart disease (11 men and two women, aged 55.8 [ ± 7.0] years), 13 male patients with Buerger's disease (aged 53.8 [ ± . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?